Our studies [16] (unpublished data) indicate that CDK9/p-TEFb inhibition is the dominant mechanism of action for three CDK inhibitors: Flavopiridol [21, 22], CAN 508 and BAY1143572, in esophageal adenocarcinoma. Here, CDK9 is linked to esophageal adenocarcinoma.